← Back to patent-cliff list
Zetomipzomib
Tier C — Watch / tradeZetomipzomib
Onyx Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Proteasome
Indications (approved)：Autoimmune hepatitis, 多发性肌炎, 皮肌炎, 狼疮肾炎, Systemic lupus erythematosus, 自身免疫疾病, Immune thrombocytopenic purpura, Autoimmune haemolytic anaemia
Regional status
US
Phase II
2018-02-20
EU
Phase II
2018-02-20
China
IND filed
2023-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zetomipzomib?
Approved indications include: Autoimmune hepatitis, 多发性肌炎, 皮肌炎, 狼疮肾炎, Systemic lupus erythematosus, 自身免疫疾病, Immune thrombocytopenic purpura, Autoimmune haemolytic anaemia.
When does the Zetomipzomib patent expire?
No public expiry year is available for Zetomipzomib yet; this page updates once verified.
How do I get a quote for Zetomipzomib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09